Carole Ben-Maimon is President and Chief Executive Officer of Larimar Therapeutics, Inc. (LRMR). The company reported total compensation of $3,526,423 for fiscal year 2025.
| Salary | $650,000 |
|---|---|
| Bonus | $307,450 |
| Stock awards | $660,860 |
| Option awards | $1,889,160 |
| Non-equity incentive plan | $0 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $18,953 |
| Total | $3,526,423 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Larimar Therapeutics, Inc. filed April 20, 2026, accession 0001193125-26-163942.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | President and Chief Executive Officer | $650,000 | $307,450 | $660,860 | $1,889,160 | $0 | $0 | $18,953 | $3,526,423 |
| FY2024 | President and Chief Executive Officer | $600,000 | $285,000 | $278,386 | $1,327,605 | $0 | $0 | $20,658 | $2,511,649 |
Totals as disclosed in each year's own compensation disclosure for Larimar Therapeutics, Inc..
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Carole Ben-Maimon this page | President and Chief Executive Officer | $3,526,423 |
| Michael Celano | Chief Financial Officer and Secretary | $1,697,960 |
| Gopi Shankar | Chief Development Officer | $1,293,329 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Larimar Therapeutics, Inc. compensation brief.
Carole Ben-Maimon's compensation sits inside Larimar Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.